Trinity Delta Lighthouse: Redx Pharma
Trinity Delta view: ROCK2 inhibition could have a role in multiple diseases and conditions associated with fibrosis. Trials are already underway in lung fibrosis and these preclinical RXC007 data provide a very early suggestion of potential in cancer-associated fibrosis models. Whilst future development plans have yet to be formalised, and will require funding, we are encouraged by the broadening indications for RXC007, Redx Pharma’s lead clinical asset. Pancreatic cancer is a challenging condition, however could be a significant commercial opportunity with a potential expedited path to market, in our view, given the unmet need. RXC007, together with RXC008, a locally acting pan-ROCK inhibitor for fibrostenotic Crohn’s disease, underpin Redx Pharma’s focus on ROCK inhibition. We continue to view these as particularly promising in the treatment of a variety of fibrosis conditions and a key component of Redx Pharma’s investment case.Redx Pharma is engaged in drug discovery, pre-clinical development and licensing. The principal activities of the business are the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. Co. is developing a porcupine inhibitor drug candidate, RXC004, as a cancer treatment using in vivo models of pancreatic and gastric cancer. ROCK1/2 inhibitors (known as systemic pan-Rock inhibitors) are known to induce hypotension. Co.'s ROCK inhibitor is designed to only work at the site of action in the gastrointestinal tract and degrades quickly, once absorbed, through enzyme-mediated metabolism in the blood, deeming it a soft inhibitor.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.